Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | MTTP | P55157 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221527 | 0.93 | ALDH1A1 (0.46) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL5455069 | 0.89 | HPGD (0.44) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL5463458 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL5457922 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL5463840 | 0.79 | ALDH1A1 (0.47) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL5345113 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL3455507 | 0.77 | MEN1 (0.62) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL6220387 | 0.77 | KCNA5 (0.39) | ALDH1A1HPGDKCNA5MAPK1MEN1 | |
| SCHEMBL2860869 | 0.76 | KCNA3 (0.62) | ALDH1A1MEN1KMT2AKCNA3 | |
| SCHEMBL5460016 | 0.75 | ALDH1A1 (0.39) | ALDH1A1HPGDKCNA5MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | ALDH1A1 4075/4885HPGD 3115/4885KCNA5 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.